

## SUPPORTING INFORMATION

# Asymmetric Cyclopropanation of Chalcones Using Chiral Phase-Transfer Catalysts

**Richard Herchl and Mario Waser\***

*Institute of Organic Chemistry, Johannes Kepler University Linz, Altenbergerstraße 69,  
4040 Linz, Austria.*

*Fax: +43 732 2468 8747; Tel: +43 732 2468 8748;*

*E-mail: Mario.waser@jku.at*

1. Experimental Details and Analytical Data: .....	2
2. NMR Spectra:.....	8
3. HPLC-Chromatograms (Chiral Stationary Phase):.....	22


## 1. Experimental Details and Analytical Data:

**General:** Melting points were measured on a Kofler melting point microscope (Reichert, Vienna). <sup>1</sup>H- and <sup>13</sup>C-NMR spectra were recorded on a Bruker Avance III 300 MHz spectrometer and on a Bruker Avance III 700 MHz spectrometer with TCI cryoprobe. All NMR spectra were referenced on the solvent peak. High resolution mass spectra were obtained using an Agilent 6520 Q-TOF mass spectrometer with an ESI source and an Agilent G1607A coaxial sprayer. All analyses were made in the positive ionization mode. Purine (exact mass for  $[M+H]^+$  = 121.050873) and 1,2,3,4,5,6-hexakis(2,2,3,3-tetrafluoropropoxy)-1,3,5,2,4,6-triazatriphosphinane (exact mass for  $[M+H]^+$  = 922.009798) were used for internal mass calibration. IR spectra were recorded on a Shimadzu IR Affinity-1 fourier transform infrared spectrometer. Optical rotations were recorded on a Perkin Elmer Polarimeter Model 241 MC. HPLC was performed using a Dionex Summit HPLC system with a Chiralcel OD-H (250 x 4.6 mm, 5  $\mu$ m) or a Chiralcel OD-R (250 x 4.6 mm, 10  $\mu$ m) chiral stationary phase. All chemicals were purchased from commercial suppliers and used without further purification unless otherwise stated. Cinchona alkaloid-based catalysts were synthesized according and in analogy to literature-known methods.<sup>1</sup> Bromomalonate-derivatives and chalcone-derivatives were synthesized according and in analogy to literature-known methods.<sup>2</sup>

---


1) a) Provencher, B. A.; Bartelson, K. J.; Liu, Y.; Foxman, B. M.; Deng, L. *Angew. Chem.* **2011**, *123*, 10753-10757; b) Fiandra, C. D.; Piras, L.; Fini, F.; Disetti, P.; Moccia, M.; Adamo, M. F. A. *Chem. Commun.* **2012**, *48*, 3863-3865; c) Li, H.; Wang, Y.; Tang, L.; Deng, L. *J. Am. Chem. Soc.* **2004**, *126*, 9906-9907; d) Liu, Y.; Provencher, B. A.; Bartelson, K. J.; Deng, L. *Chem. Sci.* **2011**, *2*, 1301-1304; e) Corey, E. J.; Xu, F.; Noe, M. C. *J. Am. Chem. Soc.* **1997**, *119*, 12414-12415; f) Berkessel, A.; Guixà, M.; Schmidt, F.; Neudörfel, J. M.; Lex. *J. Chem. Eur. J.* **2007**, *13*, 4483-4498 g) Lian, M.; Li, Z.; Du, J.; Meng, Q.; Gao, Z. *Eur. J. Org. Chem.* **2010**, 6525-6530.

2) a) Perreault, S.; Spino, C. *Org. Lett.* **2006**, *8*, 4385-4388; b) Lukoyanova, O.; Cardona, C. M.; Rivera, J.; Lugo-Morales, L. Z.; Chancellor, C. J.; Olmstead, M. M.; Rodriguez-Fortea, A.; Poblet, J. M.; Echegoyen, L. *J. Am. Chem. Soc.* **2007**, *129*, 10423-10430



**General procedure for the phase-transfer catalyzed cyclopropanation using bromomalonates and chalcones:** Reactions were usually carried out using less than 0.5 mmol bromomalonate (**1**). First 10 eq.  $K_2CO_3$  (50% aq. solution) were added to a solution of catalyst (10 mol%) in mesitylene (assuring a dilution of 0.075M based on the amount of **1** used in the reaction). After flushing the solution with Argon, the corresponding chalcone derivative (6 eq.) was added. The vigorously stirred solution (>1200 rpm) was cooled to 0°C (Ar-atmosphere). Subsequently, the bromomalonate was added in 3 portions (3x 0.33 eq. over 24 h). The biphasic mixture was stirred for a total of 46 h at 0°C. After extraction with  $CH_2Cl_2 / H_2O$ , the combined organic phases were dried over  $Na_2SO_4$ , evaporated to dryness and purified by column chromatography using heptanes:EtOAc = 40:1 to 10:1 as the eluent. The excess chalcone could easily be recovered hereby.

**(-)-3c.** Obtained as a colourless oil in 82% yield (136 mg, 0.40 mmol) and with *er* = 87:13




upon reacting chalcone **2** (615 mg, 2.96 mmol) with bromomalonate **1c** (104 mg, 0.49 mmol) in 6.4 mL mesitylene with 0.82 mL aqueous  $K_2CO_3$  solution (50% w/w). Analytical data are in accordance with those reported in literature.<sup>3</sup>  $[\alpha]_D^{20}$  -25.9 (*c* 0.44,  $CHCl_3$ );  $^1H$  NMR

(300 MHz,  $\delta$ ,  $CDCl_3$ , 298 K): 3.55 (s, 3H), 3.72 (s, 3H), 3.88 (d, *J* = 7.7 Hz, 1H), 4.14 (d, *J* = 7.7 Hz, 1H), 7.27 – 7.34 (m, 5H), 7.48 – 7.56 (m, 2H), 7.59 – 7.66 (m, 1H), 8.07 – 8.13 (m, 1H) ppm;  $^{13}C$  NMR (75 MHz,  $\delta$ ,  $CDCl_3$ , 298 K): 35.1, 36.6, 46.0, 53.0, 53.1, 127.8, 128.4, 128.5, 128.6, 128.8, 133.4, 133.8, 136.7, 166.1, 166.6, 193.9 ppm; IR (film):  $\bar{\nu}$  = 3064, 3032, 2995, 2953, 2916, 2846, 2358, 2341, 1735, 1678, 1597, 1581, 1449, 1437, 1352, 1267, 1219,

3) a) Kingsbury, C. A.; Durham, D. L.; Hutton, R.; *J. Org. Chem.* **1987**, *43*, 4696-4700; b) Ye, Y.; Zheng, C.; Fan, R. *Org. Lett.* **2009**, *11*, 3156-3159.

1178, 1117, 1024, 1010, 943, 916, 739  $\text{cm}^{-1}$ ; The enantioselectivity was determined by HPLC (Chiralcel OD-R, eluent:  $\text{H}_2\text{O}:\text{AcN} = 55:45$ , 0.7 mL/min, 10°C, retention times: (+)-enantiomer 36.4 min, (-)-enantiomer 39.6 min); HRMS (ESI):  $m/z$  calcd for  $\text{C}_{20}\text{H}_{18}\text{O}_5$ : 339.1227  $[\text{M}+\text{H}]^+$ ; found: 339.1227.


**(-)-8.** Obtained as a colourless oil in 98% yield (168 mg, 0.45 mmol) and with  $er = 88:12$



upon reacting chalcone **7** (662 mg, 2.73 mmol) with bromomalonate **1c** (97 mg, 0.46 mmol) in 6.0 mL mesitylene with 0.77 mL aqueous  $\text{K}_2\text{CO}_3$  solution (50% w/w).  $[\alpha]_{\text{D}}^{20} -11.2$  ( $c$  1.30,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR (300 MHz,  $\delta$ ,  $\text{CDCl}_3$ , 298 K): 3.59 (s, 3H), 3.71 (s, 3H), 3.84 (d,  $J =$

7.7 Hz, 1H), 4.11 (d,  $J = 7.7$  Hz, 1H), 7.22 – 7.33 (m, 4H), 7.49 – 7.57 (m, 2H), 7.60 – 7.67 (m, 1H), 8.06 – 8.12 (m, 2H) ppm;  $^{13}\text{C}$  NMR (75 MHz,  $\delta$ ,  $\text{CDCl}_3$ , 298 K): 35.1, 35.8, 46.0, 53.1, 53.1, 128.6, 128.6, 128.9, 129.9, 131.9, 133.8, 133.9, 136.6, 166.0, 166.3, 193.6 ppm; IR (film):  $\bar{\nu} = 3064, 3030, 3003, 2953, 2361, 2339, 2328, 1732, 1678, 1597, 1581, 1494, 1448, 1435, 1400, 1346, 1269, 1217, 1176, 1116, 1093, 1035, 1014, 1002, 921, 835, 769, 736$   $\text{cm}^{-1}$ ; The enantioselectivity was determined by HPLC (Chiralcel OD-R, eluent:  $\text{H}_2\text{O}:\text{AcN} = 50:50$ , 0.7 mL/min, 10 °C, retention times: (+)-enantiomer 33.8 min, (-)-enantiomer 37.9 min); HRMS (ESI):  $m/z$  calcd for  $\text{C}_{20}\text{H}_{17}\text{ClO}_5$ : 373.0837  $[\text{M}+\text{H}]^+$ ; found: 373.0836.

**(-)-10.** Obtained as a colourless oil in 91% yield (119 mg, 0.32 mmol). and with  $er = 89:11$




upon reacting chalcone **9** (497 mg, 2.05 mmol) with bromomalonate **1c** (74 mg, 0.35 mmol) in 4.6 mL mesitylene with 0.58 mL aqueous  $\text{K}_2\text{CO}_3$  solution (50% w/w).  $[\alpha]_{\text{D}}^{20} -8.5$  ( $c$  1.29,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR

(300 MHz,  $\delta$ ,  $\text{CDCl}_3$ , 298 K): 3.55 (s, 3H), 3.71 (s, 3H), 3.87 (d,  $J = 7.7$  Hz, 1H), 4.07 (d,  $J = 7.7$  Hz, 1H), 7.27 – 7.33 (m, 5H), 7.47 – 7.52 (m, 2H), 8.01 – 8.06 (m, 2H) ppm;  $^{13}\text{C}$  NMR


(75 MHz,  $\delta$ , CDCl<sub>3</sub>, 298 K): 35.0, 36.5, 46.1, 53.0, 53.1, 127.6, 127.9, 128.1, 128.5, 128.8, 129.5, 130.0, 133.2, 135.0, 140.3, 166.0, 166.4, 192.6 ppm; IR (film):  $\bar{\nu}$  = 3057, 3032, 2999, 2953, 2916, 2846, 2333, 2291, 1734, 1678, 1589, 1571, 1489, 1435, 1400, 1350, 1269, 1217, 1195, 1176, 1118, 1091, 1031, 1012, 993, 941, 921, 871, 846, 736 cm<sup>-1</sup>; The enantioselectivity was determined by HPLC (Chiralcel OD-R, eluent: H<sub>2</sub>O:AcN = 55:45, 0.7 mL/min, 10 °C, retention times: (+)-enantiomer 69.7 min, (-)-enantiomer 73.2 min); HRMS (ESI):  $m/z$  calcd for C<sub>20</sub>H<sub>17</sub>ClO<sub>5</sub>: 373.0837 [M+H]<sup>+</sup>; found: 373.0837.

**(-)-12.** Obtained as a colourless oil in 72% yield (132 mg, 0.37 mmol) and with *er* = 87:13



upon reacting chalcone **11** (689 mg, 3.05 mmol) with **1c** (108 mg, 0.51 mmol) in 6.7 mL mesitylene with 0.85 mL aqueous K<sub>2</sub>CO<sub>3</sub> solution (50% w/w). [ $\alpha$ ]<sub>D</sub><sup>20</sup> -6.1 (*c* 0.80, CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz,  $\delta$ , CDCl<sub>3</sub>, 298 K): 3.55 (s, 3H), 3.71 (s, 3H), 3.87 (d, *J* = 7.7 Hz, 1H), 4.08 (d, *J* = 7.7 Hz, 1H), 7.15 – 7.23 (m, 2H), 7.27 – 7.34 (m, 5H), 8.10 – 8.17 (m, 2H) ppm; <sup>13</sup>C NMR (75 MHz,  $\delta$ , CDCl<sub>3</sub>, 298 K): 35.0, 36.4, 46.0, 53.0, 53.1, 115.9, 116.1, 127.9, 128.5, 131.2, 131.3, 133.1, 133.1, 133.2, 166.1, 166.5, 192.1 ppm; IR (film):  $\bar{\nu}$  = 3062, 3028, 3007, 2953, 2850, 2349, 2301, 1732, 1678, 1597, 1508, 1435, 1350, 1269, 1215, 1197, 1176, 1157, 1116, 1062, 1029, 1010, 995, 941, 923, 871, 852, 817, 700 cm<sup>-1</sup>; The enantioselectivity was determined by HPLC (Chiralcel OD-H, eluent: *n*-hexane:*i*PrOH = 200:1, 0.5 mL/min, 10 °C, retention times: (-)-enantiomer 77.5 min, (+)-enantiomer 85.2 min); HRMS (ESI):  $m/z$  calcd for C<sub>20</sub>H<sub>17</sub>FO<sub>5</sub>: 357.1133 [M+H]<sup>+</sup>; found: 357.1135.


**(-)-14.** Obtained as a white solid in 59% yield (96 mg, 0.25 mmol) and with *er* = 91:9 upon



reacting chalcone **13** (638 mg, 2.52 mmol) with bromomalonate **1c** (89 mg, 0.42 mmol) in 5.5 mL mesitylene with 0.70 mL aqueous  $K_2CO_3$  solution (50% w/w).  $[\alpha]_D^{20}$  -38.4 (*c* 2.14,  $CHCl_3$ ); M.p.: decomp > 180 °C;  $^1H$  NMR (300 MHz,  $\delta$ ,  $CDCl_3$ , 298 K): 3.60 (s, 3H), 3.71 (s, 3H),

3.95 (d, *J* = 7.6 Hz, 1H), 4.18 (d, *J* = 7.6 Hz, 1H), 7.48 – 7.58 (m, 3H), 7.62 – 7.69 (m, 2H), 8.06 – 8.19 (m, 4H) ppm;  $^{13}C$  NMR (75 MHz,  $\delta$ ,  $CDCl_3$ , 298 K): 35.0, 35.4, 46.0, 53.3, 53.4, 122.9, 123.6, 128.6, 128.9, 129.5, 134.1, 135.0, 135.7, 136.4, 148.2, 165.8, 165.9, 193.1 ppm; IR (film):  $\bar{\nu}$  = 3084, 3062, 2954, 2358, 2304, 1732, 1666, 1595, 1579, 1525, 1481, 1446, 1436, 1348, 1319, 1265, 1217, 1178, 1114, 1099, 1085, 1042, 1001, 916, 902, 869, 852, 813, 788, 756, 736, 704  $cm^{-1}$ ; The enantioselectivity was determined by HPLC (Chiralcel OD-R, eluent:  $H_2O:AcN$  = 55:45, 0.7 mL/min, 10 °C, retention times: (+)-enantiomer 44.5 min, (-)-enantiomer 50.3 min); HRMS (ESI): *m/z* calcd for  $C_{20}H_{17}NO_7$ : 384.1078  $[M+H]^+$ ; found: 384.1079.

**(-)-16.** Obtained as a white solid in 58% yield (87 mg, 0.23 mmol) and with *er* = 90:10 upon




reacting chalcone **15** (590 mg, 2.34 mmol) with bromomalonate **1c** (82 mg, 0.39 mmol) in 5.1 mL mesitylene with 0.65 mL aqueous  $K_2CO_3$  solution (50% w/w).  $[\alpha]_D^{20}$  -22.8 (*c* 0.32,  $CHCl_3$ ); M.p.: decomp > 180 °C;  $^1H$  NMR (300 MHz,  $\delta$ ,  $CDCl_3$ , 298 K): 3.60 (s, 3H), 3.72 (s, 3H),

3.94 (d, *J* = 7.7 Hz, 1H), 4.18 (d, *J* = 7.7 Hz, 1H), 7.46 – 7.58 (m, 4H), 7.62 – 7.69 (m, 1H), 8.06 – 8.12 (m, 2H), 8.16 – 8.23 (m, 2H) ppm;  $^{13}C$  NMR (75 MHz,  $\delta$ ,  $CDCl_3$ , 298 K): 35.0, 35.6, 46.2, 53.3, 53.4, 123.7, 128.6, 129.0, 129.6, 134.1, 136.4, 141.0, 147.5, 165.8, 165.8, 193.1 ppm; IR (film):  $\bar{\nu}$  = 3061, 3034, 3005, 2953, 2918, 2848, 2364, 2357, 2341, 2337, 1732, 1678, 1598, 1581, 1519, 1496, 1448, 1436, 1406, 1346, 1269, 1217, 1176, 1112, 1035,


1014, 1002, 960, 939, 923, 877, 854, 738  $\text{cm}^{-1}$ ; The enantioselectivity was determined by HPLC (Chiralcel OD-R, eluent:  $\text{H}_2\text{O}:\text{AcN} = 55:45$ , 0.7 mL/min, 10  $^\circ\text{C}$ , retention times: (+)-enantiomer 54.3 min, (-)-enantiomer 70.1 min); HRMS (ESI):  $m/z$  calcd for  $\text{C}_{20}\text{H}_{17}\text{NO}_7$ : 384.1078  $[\text{M}+\text{H}]^+$ ; found: 384.1080.

**(-)-18.** Obtained as a colourless oil in 72% yield (70 mg, 0.20 mmol) and with  $er = 84:16$







upon reacting chalcone **17** (369 mg, 1.66 mmol) with bromomalonate **1c** (59 mg, 0.28 mmol) in 3.6 mL mesitylene with 0.47 mL aqueous  $\text{K}_2\text{CO}_3$  solution (50% w/w).  $[\alpha]_{\text{D}}^{20} -52.9$  ( $c = 0.09$ ,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR (300 MHz,  $\delta$ ,  $\text{CDCl}_3$ , 298 K): 2.44 (s, 3H), 3.54 (s, 3H), 3.72 (s, 3H), 3.86 (d,  $J = 7.7$  Hz, 1H), 4.12 (d,  $J = 7.7$  Hz, 1H), 7.27 – 7.36 (m, 7H), 7.97 – 8.02 (m, 2H) ppm;  $^{13}\text{C}$  NMR (75 MHz,  $\delta$ ,  $\text{CDCl}_3$ , 298 K): 12.8, 35.0, 36.6, 45.9, 52.9, 53.0, 127.7, 128.4, 128.5, 128.7, 129.5, 133.5, 134.3, 144.7, 166.2, 166.7, 193.4 ppm; IR (film):  $\bar{\nu} = 3059, 3030, 3005, 2953, 2920, 2848, 2358, 2331, 1732, 1674, 1606, 1573, 1533, 1498, 1435, 1352, 1313, 1271, 1220, 1180, 1112, 1035, 1010, 943, 921, 840, 802, 744, 700$   $\text{cm}^{-1}$ ; The enantioselectivity was determined by HPLC (Chiralcel OD-R, eluent:  $\text{H}_2\text{O}:\text{AcN} = 60:40$ , 0.7 mL/min, 10  $^\circ\text{C}$ , retention times: (+)-enantiomer 100.8 min, (-)-enantiomer 107.9 min); HRMS (ESI):  $m/z$  calcd for  $\text{C}_{21}\text{H}_{20}\text{O}_5$ : 353.1384  $[\text{M}+\text{H}]^+$ ; found: 353.1386.


## 2. NMR Spectra:






































```

NAME HER-889-05
EXPNO 21
PROCNO 1
Date_ 20121111
Time 23.30
INSTRUM spect
PROBHD 5 mm PABBO BB-
PULPROG zgpg30
TD 65536
SOLVENT CDCl3
NS 4096
DS 4
SWH 18028.846 Hz
FIDRES 0.275098 Hz
AQ 1.8175818 sec
RG 2050
DW 27.733 usec
DE 296.0 usec
TE 296.0 K
D1 2.00000000 sec
D11 0.03000000 sec

===== CHANNEL f1 =====
NUC1 13C
P1 7.13 usec
SI 32768
SF 75.4677490 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40

```

77.44  
77.22  
77.02  
76.59

53.37  
53.28

46.18

35.62  
35.04

193.05

165.83  
165.75

147.51

140.96

136.39



134.11


129.63

128.95

128.59

123.65






```

NAME      HER-892-03
EXPNO    20
PROCNO    1
Date_     20121116
Time      12.05
INSTRUM   spect
PROBHD    5 mm PABBO BB-
PULPROG   zg30
TD         65536
SFO        300.13000666 MHz
AQ         0.094423 Hz
RG         512
DE         80.800 usec
TE         296.0 K
D1         1.00000000 sec

===== CHANNEL f1 =====
NUC1      1H
P1         8.25 usec
SI         65536
SF         300.13000666 MHz
WDW        EM
SSB        0
GB         0.30 Hz
PC         1.00

```




### 3. HPLC-Chromatograms (Chiral Stationary Phase):

Operator:admin Timebase:Summit\_1 Sequence:WAS\_081112

Page 1-1  
8.11.2012 2:57 PM

#### 2 HER-886-02

Sample Name:	<b>HER-886-02</b>	Injection Volume:	<b>10,0</b>
Vial Number:	<b>RA2</b>	Channel:	<b>UV_VIS_2</b>
Sample Type:	<b>unknown</b>	Wavelength:	<b>n.a.</b>
Control Program:	<b>100min_55zu45</b>	Bandwidth:	<b>n.a.</b>
Quantif. Method:	<b>default</b>	Dilution Factor:	<b>1,0000</b>
Recording Time:	<b>8.11.2012 11:20</b>	Sample Weight:	<b>1,0000</b>
Run Time (min):	<b>89,26</b>	Flow ml/min:	<b>0,70</b>



No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount	Type
1	36,38	n.a.	88,564	93,816	10,42	n.a.	BMb*
2	39,58	n.a.	584,258	806,212	89,58	n.a.	bMB*
<b>Total:</b>			672,822	900,028	100,00	0,000	


55 Vol% H2O  
45 Vol% Acetonitril

Rueckl/Integration

Chromleon (c) Dionex 1996-2006  
Version 6.80 SR10 Build 2818 (166959)

**5 HER-863-2**

Sample Name:	HER-863-2	Injection Volume:	10,0
Vial Number:	RA1	Channel:	UV_VIS_1
Sample Type:	unknown	Wavelength:	n.a.
Control Program:	OD_R_60_50zu50	Bandwidth:	n.a.
Quantif. Method:	default	Dilution Factor:	1,0000
Recording Time:	15.10.2012 15:06	Sample Weight:	1,0000
Run Time (min):	44,34	Flow ml/min:	0,70



No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount	Type
1	33,78	n.a.	231,197	327,902	11,58	n.a.	Ru
2	37,93	n.a.	1619,946	2504,042	88,42	n.a.	BMB
<b>Total:</b>			1851,143	2831,944	100,00	0,000	

~~45 Vol% H2O~~  
~~55 Vol% Acetonitril~~


SO  
SO

Rueckl/Integration

Chromeleon (c) Dionex 1996-2006  
Version 6.80 SR10 Build 2818 (166959)

**2 HER-867-2**

Sample Name:	HER-867-2	Injection Volume:	10,0
Vial Number:	RA2	Channel:	UV_VIS_2
Sample Type:	unknown	Wavelength:	n.a.
Control Program:	100min_55zu45	Bandwidth:	n.a.
Quantif. Method:	default	Dilution Factor:	1,0000
Recording Time:	24.10.2012 11:19	Sample Weight:	1,0000
Run Time (min):	100,00	Flow ml/min:	0,70



No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount	Type
1	69,68	n.a.	112,245	225,876	11,18	n.a.	BM *
2	73,22	n.a.	740,740	1795,105	88,82	n.a.	MB*
<b>Total:</b>			852,985	2020,981	100,00	0,000	

55 Vol% H2O  
45 Vol% Acetonitril


Rueckl/Integration

Chromeleon (c) Dionex 1996-2006  
Version 6.80 SR10 Build 2818 (166959)



**5 HER-884-02**

Sample Name:	<b>HER-884-02</b>	Injection Volume:	<b>10,0</b>
Vial Number:	<b>RA1</b>	Channel:	<b>UV_VIS_2</b>
Sample Type:	<b>unknown</b>	Wavelength:	<b>n.a.</b>
Control Program:	<b>100min_55zu45</b>	Bandwidth:	<b>n.a.</b>
Quantif. Method:	<b>default</b>	Dilution Factor:	<b>1,0000</b>
Recording Time:	<b>8.11.2012 14:03</b>	Sample Weight:	<b>1,0000</b>
Run Time (min):	<b>68,17</b>	Flow ml/min:	<b>0,70</b>




No.	Ret. Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount	Type
1	44,51	n.a.	26,727	42,069	8,89	n.a.	BMB
2	50,28	n.a.	246,803	431,181	91,11	n.a.	BMB
<b>Total:</b>			273,529	473,251	100,00	0,000	

55 Vol% H<sub>2</sub>O  
45 Vol% Acetonitril

**1 HER-889-05**

Sample Name:	HER-889-05	Injection Volume:	10,0
Vial Number:	RA1	Channel:	UV_VIS_2
Sample Type:	unknown	Wavelength:	n.a.
Control Program:	120min_55zu45	Bandwidth:	n.a.
Quantif. Method:	default	Dilution Factor:	1,0000
Recording Time:	14.11.2012 9:37	Sample Weight:	1,0000
Run Time (min):	120,00	Flow ml/min:	0,70



No.	Ret.Time min	Peak Name	Height mAU	Area mAU*min	Rel.Area %	Amount	Type
1	54,30	n.a.	5,510	9,930	10,13	n.a.	BMB*
2	70,06	n.a.	38,117	88,056	89,87	n.a.	BMB
<b>Total:</b>			43,627	97,986	100,00	0,000	

55 Vol% H<sub>2</sub>O  
45 Vol% Acetonitril